BiotechTube

Mirabegron + Tolterodine ER

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Overactive Bladder (OAB)

Conditions

Overactive Bladder (OAB)

Trial Timeline

Jul 24, 2014 → Nov 11, 2015

NCT ID
NCT02138747

About Mirabegron + Tolterodine ER

Mirabegron + Tolterodine ER is a approved stage product being developed by Astellas Pharma for Overactive Bladder (OAB). The current trial status is completed. This product is registered under clinical trial identifier NCT02138747. Target conditions include Overactive Bladder (OAB).

What happened to similar drugs?

20 of 20 similar drugs in Overactive Bladder (OAB) were approved

Approved (20) Terminated (1) Active (0)
✅mirabegron + solifenacinAstellas PharmaApproved
✅Mirabegron + PlaceboAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
✅SolifenacinAstellas PharmaApproved
✅Alpha blocker + placebo + solifenacinAstellas PharmaApproved
✅Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved
✅Solifenacin succinateAstellas PharmaApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02138747ApprovedCompleted

Competing Products

20 competing products in Overactive Bladder (OAB)

See all competitors
ProductCompanyStageHype Score
mirabegron + solifenacinAstellas PharmaApproved
43
Mirabegron + PlaceboAstellas PharmaApproved
43
SolifenacinAstellas PharmaApproved
43
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
40
solifenacin succinateAstellas PharmaPhase 3
40
SolifenacinAstellas PharmaPre-clinical
26
BetanisAstellas PharmaPre-clinical
26
SolifenacinAstellas PharmaApproved
43
SolifenacinAstellas PharmaPhase 2
35
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
26
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
43
warfarin + YM178Astellas PharmaPhase 1
29
Solifenacin succinateAstellas PharmaPhase 3
40
solifenacin succinate + tolterodineAstellas PharmaPhase 3
40
Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved
43
Solifenacin succinateAstellas PharmaApproved
43
Mirabegron + PlaceboAstellas PharmaPhase 3
32
SolifenacinAstellas PharmaPre-clinical
26
Solifenacin succinate + TolterodineAstellas PharmaPhase 3
40
Solifenacin succinate + PlaceboAstellas PharmaPhase 3
40